FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2524359675> ?p ?o ?g. }

• W2524359675 abstract "Abstract Thrombotic thrombocytopenic purpura (TTP) is a life threatening disorder characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with a deficiency in ADAMTS 13. Plasma exchange (PEX) remains the primary treatment modality in acute TTP, with various immunosuppressive agents (e.g. methylprednisolone, vincristine, ciclosporin (CSA)) and other disease modifying agents(e.g. defibrotide), added in refractory cases. However, mortality remains at 15–20%. Rituximab is a monoclonal CD 20 antibody, which acts specifically to clear peripheral B lymphocytes involved with antibody production. We have treated 15 patients with acute refractory TTP; 12 female and 3 male, with 2–8 weekly Rituximab infusions, 375mg/m2. Fourteen had neurological features and 3 had cardiac TTP at presentation. Patients received Rituximab because of progressive clinical disease or deterioration of laboratory parameters despite intensive therapy. On admission, median haemoglobin was 8.2 (range 5.1–12) g/dl, platelet count 14 (range 3–70) X 109/L, lactate dehydrogenase (LDH) 1620 (range 411–>2832) IU/L. All patients attained normal laboratory parameters and clinical remission within 22 days of starting Rituximab therapy. Three patients proceeded to further Rituximab based on ADAMTS 13 activity following 4 treatments. Twelve patients had initial ADAMTS 13 activities <5% (normal range (NR) 66–126% by collagen binding assay) and thirteen patients had normal ADAMTS 13 activity (median 78%) following Rituximab. IgG antibodies to ADAMTS 13 pre Rituximab were detected in thirteen patients but were undetectable post Rituximab. The median number of PEX pre Rituximab was 14 (1–35) and following the first Rituximab treatment, 6 (1–22), including weaning with an alternate day regime following clinical and laboratory remission. This difference was significant (p=0.042, Wilcoxon signed ranks test). To date (follow-up 1–27 months) there have been no TTP relapses. No significant decrease in CD 19 levels, immunoglobulin levels or infectious complications have been documented. These data suggest that patients with acute refractory TTP respond promptly to Rituximab, associated with a significant reduction in the requirement for PEX. Clinical and haematological remission was demonstrated and maintained within 3 weeks of Rituximab treatment in all patients. Only one patient failed to increment ADAMTS 13 activity. In all patients with IgG antibodies to ADAMTS 13, these disappeared within 28 days of Rituximab treatment. Rituximab therefore appears to be a safe, effective, targeted therapy for acute refractory TTP." @default.
• W2524359675 created "2016-10-07" @default.
• W2524359675 creator A5038132058 @default.
• W2524359675 creator A5043135271 @default.
• W2524359675 creator A5043865060 @default.
• W2524359675 creator A5061278813 @default.
• W2524359675 creator A5072352891 @default.
• W2524359675 creator A5081233146 @default.
• W2524359675 creator A5085260147 @default.
• W2524359675 date "2005-11-16" @default.
• W2524359675 modified "2023-09-27" @default.
• W2524359675 title "Normalisation of ADAMTS 13 Activity and Disappearance of ADAMTS 13 Antibody Following Rituximab in Acute Refractory Thrombotic Thrombocytopenic Purpura." @default.
• W2524359675 doi "https://doi.org/10.1182/blood.v106.11.1230.1230" @default.
• W2524359675 hasPublicationYear "2005" @default.
• W2524359675 type Work @default.
• W2524359675 sameAs 2524359675 @default.
• W2524359675 citedByCount "1" @default.
• W2524359675 crossrefType "journal-article" @default.
• W2524359675 hasAuthorship W2524359675A5038132058 @default.
• W2524359675 hasAuthorship W2524359675A5043135271 @default.
• W2524359675 hasAuthorship W2524359675A5043865060 @default.
• W2524359675 hasAuthorship W2524359675A5061278813 @default.
• W2524359675 hasAuthorship W2524359675A5072352891 @default.
• W2524359675 hasAuthorship W2524359675A5081233146 @default.
• W2524359675 hasAuthorship W2524359675A5085260147 @default.
• W2524359675 hasConcept C121332964 @default.
• W2524359675 hasConcept C126322002 @default.
• W2524359675 hasConcept C142424586 @default.
• W2524359675 hasConcept C159654299 @default.
• W2524359675 hasConcept C203014093 @default.
• W2524359675 hasConcept C2778585876 @default.
• W2524359675 hasConcept C2780372218 @default.
• W2524359675 hasConcept C2780653079 @default.
• W2524359675 hasConcept C2781127562 @default.
• W2524359675 hasConcept C65245452 @default.
• W2524359675 hasConcept C71924100 @default.
• W2524359675 hasConcept C87355193 @default.
• W2524359675 hasConcept C89560881 @default.
• W2524359675 hasConcept C90924648 @default.
• W2524359675 hasConceptScore W2524359675C121332964 @default.
• W2524359675 hasConceptScore W2524359675C126322002 @default.
• W2524359675 hasConceptScore W2524359675C142424586 @default.
• W2524359675 hasConceptScore W2524359675C159654299 @default.
• W2524359675 hasConceptScore W2524359675C203014093 @default.
• W2524359675 hasConceptScore W2524359675C2778585876 @default.
• W2524359675 hasConceptScore W2524359675C2780372218 @default.
• W2524359675 hasConceptScore W2524359675C2780653079 @default.
• W2524359675 hasConceptScore W2524359675C2781127562 @default.
• W2524359675 hasConceptScore W2524359675C65245452 @default.
• W2524359675 hasConceptScore W2524359675C71924100 @default.
• W2524359675 hasConceptScore W2524359675C87355193 @default.
• W2524359675 hasConceptScore W2524359675C89560881 @default.
• W2524359675 hasConceptScore W2524359675C90924648 @default.
• W2524359675 hasLocation W25243596751 @default.
• W2524359675 hasOpenAccess W2524359675 @default.
• W2524359675 hasPrimaryLocation W25243596751 @default.
• W2524359675 hasRelatedWork W1966265735 @default.
• W2524359675 hasRelatedWork W1978735639 @default.
• W2524359675 hasRelatedWork W2049858156 @default.
• W2524359675 hasRelatedWork W2083670536 @default.
• W2524359675 hasRelatedWork W2096103309 @default.
• W2524359675 hasRelatedWork W2292506600 @default.
• W2524359675 hasRelatedWork W2792440265 @default.
• W2524359675 hasRelatedWork W2800869282 @default.
• W2524359675 hasRelatedWork W3008463185 @default.
• W2524359675 hasRelatedWork W3187781154 @default.
• W2524359675 isParatext "false" @default.
• W2524359675 isRetracted "false" @default.
• W2524359675 magId "2524359675" @default.
• W2524359675 workType "article" @default.